US8633309 — Nucleoside phosphoramidates
Method of Use · Assigned to Gilead Pharmasset LLC · Expires 2029-03-26 · 3y remaining
What this patent protects
This patent protects nucleoside phosphoramidates and their use as agents for treating viral diseases, specifically hepatitis C infection in mammals.
USPTO Abstract
Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1470 |
— | |
U-1470 |
— | |
U-1470 |
— | |
U-1470 |
— | |
U-1470 |
— | |
U-1470 |
— | |
U-1470 |
— | |
U-1470 |
— | |
U-1470 |
— | |
U-1470 |
— | |
U-2039 |
— | |
U-1470 |
— | |
U-1470 |
— |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.